Summary & Overview
CPT 94640: Inhalation Treatment for Acute Airway Obstruction or Sputum Induction
CPT code 94640 covers pressurized or nonpressurized inhalation treatments for acute airway obstruction or sputum induction, a critical procedure in pulmonary care. This code is widely recognized across major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The procedure is typically performed in an office setting and is essential for both therapeutic intervention and diagnostic evaluation of respiratory conditions.
Readers will gain insight into payer coverage, clinical indications, and policy benchmarks related to 94640. The publication details associated ICD-10 diagnoses, relevant modifiers, and related CPT codes, providing a comprehensive overview of billing and clinical context. Updates on payer policies and coding practices are included to inform stakeholders about current trends and requirements. The analysis highlights the importance of accurate coding for pulmonary therapies and diagnostic procedures, ensuring compliance and optimal reimbursement across the healthcare landscape.
CPT Code Overview
CPT code 94640 is used to report pressurized or nonpressurized inhalation treatments for acute airway obstruction or for sputum induction for diagnostic purposes. These treatments may involve the use of an aerosol generator, nebulizer, metered dose inhaler, or intermittent positive pressure breathing (IPPB) device. The service type is Pulmonary Diagnostic Testing and Therapies, and the typical site of service is the office setting (Place of Service 11). This code is commonly utilized in clinical scenarios where rapid intervention or diagnostic evaluation of the respiratory system is required.
Clinical & Coding Specifications
Clinical Context
A patient presents to the office with symptoms of acute airway obstruction, such as wheezing, shortness of breath, or productive cough. The provider determines that an inhalation treatment is necessary to relieve airway obstruction or to induce sputum for diagnostic evaluation. The procedure is performed using an aerosol generator, nebulizer, metered dose inhaler, or intermittent positive pressure breathing (IPPB) device. The clinical workflow involves assessment, administration of the inhalation treatment, monitoring of the patient's response, and documentation of the procedure. This service is typically provided by a respiratory therapist or pulmonary function technologist in an office setting.
Coding Specifications
-
Modifier
25: Used when a significant, separately identifiable evaluation and management service is performed by the same physician on the same day as the inhalation treatment. -
Modifier
59: Used to indicate a distinct procedural service, such as when the inhalation treatment is performed separately from other procedures.
| Modifier Code | Description |
|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Same Day of the Procedure or Other Service |
59 | Distinct Procedural Service |
Associated Provider Taxonomies:
2279P1005X- Pulmonary Rehabilitation Registered Respiratory Therapist2279P1006X- Pulmonary Function Technologist Registered Respiratory Therapist
These specialties represent professionals trained in pulmonary rehabilitation and pulmonary function testing, respectively.
Related Diagnoses
-
A15.0- Tuberculosis of lung- Relevant for patients requiring inhalation treatment due to pulmonary tuberculosis.
-
A22.1- Pulmonary anthrax- Inhalation therapy may be indicated for acute airway obstruction in pulmonary anthrax.
-
A37.01- Whooping cough due to Bordetella pertussis with pneumonia- Inhalation treatment can help manage airway obstruction in pertussis with pneumonia.
-
A37.11- Whooping cough due to Bordetella parapertussis with pneumonia- Similar clinical relevance as above for airway management.
-
A37.81- Whooping cough due to other Bordetella species with pneumonia- Inhalation therapy may be used for acute symptoms.
-
A37.91- Whooping cough, unspecified species with pneumonia- Airway obstruction may require inhalation treatment.
-
A48.1- Legionnaires’ disease- Inhalation therapy may assist in managing respiratory symptoms.
-
B25.0- Cytomegaloviral pneumonitis- Used for acute airway obstruction or sputum induction in viral pneumonitis.
-
B44.0- Invasive pulmonary aspergillosis- Inhalation treatment may be necessary for airway management.
-
B77.81- Ascariasis pneumonia- Airway obstruction from parasitic infection may require inhalation therapy.
-
C34.11- Malignant neoplasm of upper lobe, right bronchus or lung- Inhalation treatment may be used for airway obstruction or sputum induction in lung cancer.
-
C34.12- Malignant neoplasm of upper lobe, left bronchus or lung- Similar clinical relevance as above.
-
C34.2- Malignant neoplasm of middle lobe, bronchus or lung- Inhalation therapy may be indicated for airway management.
-
C34.31- Malignant neoplasm of lower lobe, right bronchus or lung- Used for airway obstruction or sputum induction.
-
C34.32- Malignant neoplasm of lower lobe, left bronchus or lung- Clinical relevance as above.
-
C34.80- Malignant neoplasm of overlapping sites of unspecified bronchus and lung- Inhalation treatment may be required for complex lung neoplasms.
-
C34.81- Malignant neoplasm of overlapping sites of right bronchus and lung- Used for airway management in overlapping neoplastic sites.
-
C34.82- Malignant neoplasm of overlapping sites of left bronchus and lung- Similar clinical relevance as above.
-
C34.91- Malignant neoplasm of unspecified part of right bronchus or lung- Inhalation therapy may be indicated for airway obstruction.
-
C34.92- Malignant neoplasm of unspecified part of left bronchus or lung- Used for airway management or sputum induction.
-
C38.4- Malignant neoplasm of pleura- Inhalation treatment may assist in managing respiratory symptoms.
-
C45.0- Mesothelioma of pleura- Airway obstruction or sputum induction may require inhalation therapy.
-
C78.01- Secondary malignant neoplasm of right lung- Used for airway management in metastatic lung disease.
-
C78.02- Secondary malignant neoplasm of left lung- Similar clinical relevance as above.
Related CPT Codes
-
94060- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration- Used to assess lung function before and after bronchodilator administration; may be performed in conjunction with inhalation treatment (
94640) to evaluate response.
- Used to assess lung function before and after bronchodilator administration; may be performed in conjunction with inhalation treatment (
-
94664- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device- Used to educate and assess patient technique with inhalation devices; often performed alongside or prior to
94640.
- Used to educate and assess patient technique with inhalation devices; often performed alongside or prior to
-
94760- Noninvasive ear or pulse oximetry for oxygen saturation; single determination- Used to monitor oxygen saturation during or after inhalation treatment; commonly used together with
94640.
- Used to monitor oxygen saturation during or after inhalation treatment; commonly used together with
-
94762- Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring- Used for extended monitoring of oxygen saturation, typically in patients with ongoing respiratory issues; may be used as an alternative or adjunct to
94640depending on clinical needs.
- Used for extended monitoring of oxygen saturation, typically in patients with ongoing respiratory issues; may be used as an alternative or adjunct to
National Reimbursement Benchmarks
National mean rates for CPT code 94640 show a significant gap between Medicare and commercial payers. Medicare's mean rate is $9.02, while the average commercial mean rate (BUCA) is $21.59, more than double the Medicare rate. UnitedHealth Group has the highest mean rate at $26.28, and Blue Cross Blue Shield is the lowest among commercial payers at $16.50.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Medicare has the tightest range ($1.00), indicating minimal variation in rates. Blue Cross Blue Shield also shows a relatively narrow range ($9.67). In contrast, UnitedHealth Group exhibits the widest dispersion ($15.00), followed by Aetna ($18.00), suggesting greater variability in commercial reimbursement rates.
The table and chart below present the full breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.